Novel thrombin and factor Xa inhibitors: Challenges to reversal of their anticoagulation effects

Sean Yates, Ravi Sarode

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Warfarin has been the sole oral anticoagulant used in the management of thromboembolic disorders for over 60 years. Target-specific oral anticoagulants (TSOAs) have recently emerged as alternatives to warfarin, because they do not require laboratory monitoring. Nevertheless, with the rising use of TSOAs, there is growing concern among clinicians regarding management of bleeding in patients taking them. Unlike warfarin, there is no antidote or reversal agent for TSOAs. This review summarizes recent developments and attempts to provide a systematic approach to patients on TSOAs presenting with bleeding complications. RECENT FINDINGS: Currently, data involving clinical management of TSOAs are limited and primarily based on ex-vivo or animal models using hemostatic agents with uncertain implications in bleeding patients. There is a pressing need for randomized clinical trials evaluating the safety and efficacy of hemostatic agents. SUMMARY: Without evidence-based guidelines for TSOA management, appropriate patient care requires an understanding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation of test results, as well as a systematic approach to bleeding complications.

Original languageEnglish (US)
Pages (from-to)552-557
Number of pages6
JournalCurrent Opinion in Hematology
Volume20
Issue number6
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Thrombin
Anticoagulants
Warfarin
Hemorrhage
Hemostatics
Patient Care Management
Antidotes
Factor Xa Inhibitors
Randomized Controlled Trials
Animal Models
Pharmacology
Guidelines
Safety

Keywords

  • apixaban
  • dabigatran
  • oral anticoagulants
  • prothrombin complex concentrate
  • rivaroxaban
  • warfarin

ASJC Scopus subject areas

  • Hematology

Cite this

Novel thrombin and factor Xa inhibitors : Challenges to reversal of their anticoagulation effects. / Yates, Sean; Sarode, Ravi.

In: Current Opinion in Hematology, Vol. 20, No. 6, 11.2013, p. 552-557.

Research output: Contribution to journalReview article

@article{7a977e1d65e14442899a97409824be94,
title = "Novel thrombin and factor Xa inhibitors: Challenges to reversal of their anticoagulation effects",
abstract = "PURPOSE OF REVIEW: Warfarin has been the sole oral anticoagulant used in the management of thromboembolic disorders for over 60 years. Target-specific oral anticoagulants (TSOAs) have recently emerged as alternatives to warfarin, because they do not require laboratory monitoring. Nevertheless, with the rising use of TSOAs, there is growing concern among clinicians regarding management of bleeding in patients taking them. Unlike warfarin, there is no antidote or reversal agent for TSOAs. This review summarizes recent developments and attempts to provide a systematic approach to patients on TSOAs presenting with bleeding complications. RECENT FINDINGS: Currently, data involving clinical management of TSOAs are limited and primarily based on ex-vivo or animal models using hemostatic agents with uncertain implications in bleeding patients. There is a pressing need for randomized clinical trials evaluating the safety and efficacy of hemostatic agents. SUMMARY: Without evidence-based guidelines for TSOA management, appropriate patient care requires an understanding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation of test results, as well as a systematic approach to bleeding complications.",
keywords = "apixaban, dabigatran, oral anticoagulants, prothrombin complex concentrate, rivaroxaban, warfarin",
author = "Sean Yates and Ravi Sarode",
year = "2013",
month = "11",
doi = "10.1097/MOH.0b013e328365a164",
language = "English (US)",
volume = "20",
pages = "552--557",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Novel thrombin and factor Xa inhibitors

T2 - Challenges to reversal of their anticoagulation effects

AU - Yates, Sean

AU - Sarode, Ravi

PY - 2013/11

Y1 - 2013/11

N2 - PURPOSE OF REVIEW: Warfarin has been the sole oral anticoagulant used in the management of thromboembolic disorders for over 60 years. Target-specific oral anticoagulants (TSOAs) have recently emerged as alternatives to warfarin, because they do not require laboratory monitoring. Nevertheless, with the rising use of TSOAs, there is growing concern among clinicians regarding management of bleeding in patients taking them. Unlike warfarin, there is no antidote or reversal agent for TSOAs. This review summarizes recent developments and attempts to provide a systematic approach to patients on TSOAs presenting with bleeding complications. RECENT FINDINGS: Currently, data involving clinical management of TSOAs are limited and primarily based on ex-vivo or animal models using hemostatic agents with uncertain implications in bleeding patients. There is a pressing need for randomized clinical trials evaluating the safety and efficacy of hemostatic agents. SUMMARY: Without evidence-based guidelines for TSOA management, appropriate patient care requires an understanding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation of test results, as well as a systematic approach to bleeding complications.

AB - PURPOSE OF REVIEW: Warfarin has been the sole oral anticoagulant used in the management of thromboembolic disorders for over 60 years. Target-specific oral anticoagulants (TSOAs) have recently emerged as alternatives to warfarin, because they do not require laboratory monitoring. Nevertheless, with the rising use of TSOAs, there is growing concern among clinicians regarding management of bleeding in patients taking them. Unlike warfarin, there is no antidote or reversal agent for TSOAs. This review summarizes recent developments and attempts to provide a systematic approach to patients on TSOAs presenting with bleeding complications. RECENT FINDINGS: Currently, data involving clinical management of TSOAs are limited and primarily based on ex-vivo or animal models using hemostatic agents with uncertain implications in bleeding patients. There is a pressing need for randomized clinical trials evaluating the safety and efficacy of hemostatic agents. SUMMARY: Without evidence-based guidelines for TSOA management, appropriate patient care requires an understanding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation of test results, as well as a systematic approach to bleeding complications.

KW - apixaban

KW - dabigatran

KW - oral anticoagulants

KW - prothrombin complex concentrate

KW - rivaroxaban

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=84885403809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885403809&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e328365a164

DO - 10.1097/MOH.0b013e328365a164

M3 - Review article

C2 - 24104417

AN - SCOPUS:84885403809

VL - 20

SP - 552

EP - 557

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 6

ER -